logo
Paradromics implants brain-computer interface into first human patient

Paradromics implants brain-computer interface into first human patient

Yahoo3 days ago

June 2 (UPI) -- Paradromics, a competitor of Neuralink, announced Monday it safely implanted a brain-computer interface into a human patient and recorded neural activity, before removing it 10 minutes later.
The surgical procedure, performed May 14 at the University of Michigan, marks the first time Paradromics has temporarily implanted its device -- called Connexus -- into a human with the goal of restoring neural signals in patients with spinal cord injuries, stroke or ALS. Until last month, the Austin-based startup had only implanted and tested the device on sheep.
"We've shown in sheep that our device is best in class from a data and longevity standpoint, and now we've also shown that it's compatible with humans," Matt Angle, Paradromics founder and chief executive officer, told CNBC.
Last year, Elon Musk's Neuralink became the first to implant a brain-computer interface into a human patient. Noland Arbaugh, who was paralyzed in an accident in 2016, received "the Link" implant in January 2024. Since then, Arbaugh has been using it for up to eight hours a day and is able to do a variety of digital tasks.
Brain-computer interface companies Precision Neuroscience and Synchron, which is backed by Jeff Bezos and Bill Gates, have also implanted their systems into humans. While brain-computer interfaces interpret neural signals associated with movement, they do not read thoughts.
Connexus, which is smaller than a dime and has 420 small electrodes, is embedded directly into the surrounding brain tissue. Paradromics' BCI records brain activity at the level of individual neurons.
"By having proximity to the individual neurons, you can get the highest-quality signal," said Angle.
The patient, who received last month's Connexus implant, was already undergoing neurosurgery to treat epilepsy and consented to the research, allowing doctors to temporarily implant the device into their temporal lobe.
"There's a very unique opportunity when someone is undergoing a major neurosurgical procedure," said Angle. "They're going to have their skull opened up, and there's going to be a piece of brain that will be imminently removed. Under these conditions, the marginal risk of testing out a brain implant is actually very low."
While Paradromics' Connexus implant is still being reviewed by regulators, research institutions such as the University of Michigan are allowed to use the devices as long as they prove there is no significant risk to the patient.
"You do all of these steps, you validate the hardware, you have this really high degree of rational certainty that things are going to work," Angle said, "but still emotionally when it works and when it happens the way you expected it to, it's still very, very gratifying."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030
$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030

Yahoo

time25 minutes ago

  • Yahoo

$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030

The human microbiome-based drugs and diagnostics market is projected to grow from $393.4M in 2025 to $1.2B by 2030, at a CAGR of 25.6%. Key players include Ferring, Nestlé Health Science, and Vedanta Biosciences. The report covers market trends, competitive landscape, and ESG developments. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome-based Drugs and Diagnostics: Global Markets" report has been added to global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030. The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestle Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Scope 55 data tables and 51 additional tables Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes An analysis of the key patent grants and recently published patents Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook Profiles of the leading companies, including Ferring Pharmaceuticals, Nestle Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc. Companies Featured BiomeBank EnteroBiotix Ltd. Enterome Ferring Genetic Analysis Illumina Inc. Microbiome Insights Microbiotica Nestle Health Science Oxford Nanopore Technologies plc PacBio SFA Therapeutics Inc. Thermo Fisher Scientific Inc. Vedanta Biosciences Inc. Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Market Dynamics Emerging Technologies Analysis by Segment Regional Analysis Conclusion Chapter 2 Market Overview Overview and Market Definition Different Microbiomes in Humans Microbiome, Human Health and Disease Technologies Aiding Microbiome Research Culturing and Cultivation Strategies for the Development of Microbiome Therapeutics Additive Microbiome Therapy Modulatory Microbiome Therapy Analysis of Macroeconomic Factors Geopolitical Factors Inflation and Currency Exchange Fluctuations Porter's Five Forces Analysis Chapter 3 Market Dynamics Takeaways Market Drivers Growing Evidence of Microbiome-disease Correlation Microbiome-based Diagnostics for Disease Prevention and Monitoring Market Restraints Challenges in Clinical Trial Design Lack of Established Regulatory Frameworks High Costs of Microbiome Therapeutics Market Opportunities Direct-to-Consumer Microbiome Testing Drugs and Diagnostics for Lung and Skin Microbiomes Chapter 4 Regulatory Landscape Regulatory Aspects North America Europe Asia-Pacific Chapter 5 Emerging Technologies Takeaways Emerging Technologies Microbial Ecosystem Therapeutics Metatranscriptome Sequencing Genetically Modified Microbiome Therapeutics Combination and Adjuvant Therapies with Microbiome-based Drugs Novel Preclinical Models Chapter 6 Market Segmentation Analysis Segmentation Breakdown Market Analysis by Type Microbiome-based Drugs Market Analysis by Application Infectious Diseases GI Disorders Metabolic Disorders Cancer Other Diseases Market Analysis by End User Hospitals and Clinics Research Institutions Pharmaceutical Companies Geographic Breakdown Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Takeaways Company Share Analysis Competitive Analysis Venture Funding and Investment Landscape Recent Developments Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective Introduction to ESG ESG Risk Ratings Concluding Remarks Chapter 9 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

Citigroup to axe around 3,500 tech roles in China
Citigroup to axe around 3,500 tech roles in China

Yahoo

time25 minutes ago

  • Yahoo

Citigroup to axe around 3,500 tech roles in China

Citigroup is trimming its workforce size by approximately 3,500 at two of its technology centres in China, reported Reuters. The aim is to consolidate and streamline the bank's global technology operations to enhance its risk and data management systems. The staffing reductions will affect the China Citi Solution Centres in Shanghai and Dalian, with the bank planning to complete the process by the start of the fourth quarter of this year, the news agency said citing a statement by Citi. The jobs being cut are predominantly full-time positions, a source privy to the development disclosed. Some of the jobs from these centres would be relocated to other technology hubs within the company, although the specifics regarding the number of jobs or their destinations were not provided. This announcement follows last month's report, which indicated that Citigroup was reducing around 200 information technology contractor roles in China. In March, the bank communicated internally its strategy to decrease its reliance on IT contractors and to increase its in-house IT staff, in response to penalties imposed by regulators concerning data governance and control shortcomings. The downsizing in China is part of Citigroup's global restructuring plan, which has also seen the bank scaling back operations in the US, Indonesia, the Philippines, and Poland. The China-based service and technology unit is tasked with delivering financial technology and operations services to support Citigroup's global business operations. Citigroup is currently in the process of establishing a securities unit in China, still maintain the regional presence. Post-reduction, Citigroup's staff count in China is expected to be around 2,000, which includes several hundred employees within the technology division. Citi Japan, Asia North and Australia banking head Marc Luet was quoted by Reuters as saying: "Citi continues to pursue the establishment of a wholly owned securities and futures company in China." "Citigroup to axe around 3,500 tech roles in China " was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Powering Retail's Future: PXP Brings Castles Technology's Android Terminals to Global Merchants
Powering Retail's Future: PXP Brings Castles Technology's Android Terminals to Global Merchants

Business Wire

timean hour ago

  • Business Wire

Powering Retail's Future: PXP Brings Castles Technology's Android Terminals to Global Merchants

LONDON--(BUSINESS WIRE)--PXP, a next-gen payment platform, today announces a strategic collaboration with Castles Technology, bringing cutting-edge Android-based terminal technology to merchants of all sizes across diverse point-of-sale environments. This powerful partnership combines PXP's innovative payment expertise with Castles Technology's advanced hardware engineering to deliver a seamless, secure payment experience that elevates customer engagement in every business context. "We're excited to partner with Castles Technology to expand our hardware ecosystem and bring these innovative Android payment solutions to our customers," said Kamran Hedjri, CEO at PXP. 'From day one, Castles Technology has distinguished themselves as an extraordinarily responsive and collaborative partner. Their team's unwavering commitment to excellence, technical expertise, and customer-first approach perfectly mirrors our own values, making this collaboration particularly powerful. "This partnership represents our commitment to providing merchants with the most advanced, reliable, and user-friendly payment technologies in today's rapidly evolving marketplace. As we continue to build on our tech-first approach following the launch of PXP Unity and our recent PXP POS standalone solution, this partnership aligns perfectly with our vision of creating a truly unified global commerce ecosystem." The collaboration brings PXP's platform together with Castles Technology's latest Saturn terminal range, creating a solution that elevates payment experiences through: Cutting-Edge Technology Access: Merchants gain immediate access to state-of-the-art Android payment terminals featuring the latest security protocols, intuitive interfaces, and enhanced customer engagement features. Versatile Terminal Solutions: The new terminal lineup includes sleek, space-efficient designs engineered for today's point-of-sale environments, offering enhanced connectivity, lightning-fast transaction processing, and support across multiple form factors including mobile, countertop, and unattended terminals. Streamlined Implementation: This partnership delivers a significantly expedited fulfillment process, with faster equipment delivery and setup, minimising business disruption and accelerating time-to-value for merchants of all sizes. Unified Commerce Experience: PXP will embed real-time data insights and granular control over merchants' payment ecosystem across all channels into the solution, breaking down borders and unifying commerce operations worldwide. James Lotz, SVP Northern & Western Europe added, "Our collaboration with PXP creates a powerful opportunity to extend our reach and equip merchants with Android payment terminals specifically designed for today's demanding instore landscape. We're proud to support PXP's customers with our innovative hardware solutions that combine security, reliability, and enhanced user experience." The announcement comes at a pivotal moment for PXP, following the company's recent brand transformation and the successful launch of its groundbreaking PXP Unity platform earlier this year. The new Android terminal offerings will be available to PXP customers starting May 2025, complementing the recently launched PXP POS standalone solution as part of the company's strategic expansion of its point-of-sale ecosystem. This integration aligns with PXP's vision to deliver comprehensive payment solutions that meet evolving merchant needs across all channels. For more information, please visit or About PXP PXP is a tech platform that makes commerce simpler, better, and more connected. With just one connection to PXP, merchants can unlock a world of commerce across online, mobile, and point-of-sale channels. Powered by a suite of financial services, multiple acquiring connections—including an in-house acquiring license—and diverse alternative payment methods, PXP processes over €30 billion annually through our unified gateway. Connect once to our global commerce ecosystem to supercharge your growth by unifying payments, streamlining operations, and getting access endless opportunities. Learn more about the PXP family of companies at: About Castles Technology Castles Technology is a global leader in payment acceptance solutions, providing cutting-edge terminals, innovative solutions, and differentiated services to strengthen the payment ecosystem. Present in 150 countries and with a team of over 1,000 employees, Castles Technology partners with thousands of clients—including banks, merchants, FinTechs, acquirers, ISVs, and PSPs—to deploy millions of point-of-sale terminals worldwide, catering to businesses of all sizes. As a pioneer in Android payment acceptance, Castles Technology delivers secure, reliable, and scalable solutions, having recently launched its third generation of Android terminals. With over 30 years of expertise, the company continues to drive the evolution of commerce by developing state-of-the-art payment solutions and first-class services, ensuring unmatched quality and performance for its partners. Committed to a more sustainable future, Castles Technology integrates eco-design into its products, optimizes operations, and develops responsible services to minimize its environmental footprint and create a positive impact on the planet.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store